Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia

International Urology and Nephrology

Volumn 28, Issue 6, 1996, Pages 767-772

  Kondas J ^a   Philipp, V ^a   Dioszeghy G ^a  

^a Péterfy Sándor Street Hospital   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; MALE; PROSTATE HYPERTROPHY; SABAL;

EID: 0030430669     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02550725     Document Type: Article

References (15)

1. Bach, D.: Medicamentöse Langzeitbehandlung der BPH. Ergebnisse einer prospectiven 3-Jahresstudie mit dem Sabalextrakt IDS 89. Urologe [B], 35, 178 (1995).
2. Berry, S. J., Coffey, D. S., Walsh, P. C., Ewing, L. L.: The development of human benign prostatic hyperplasia with age. J. Urol., 132, 474 (1984).
3. Boyle, P., Denis, L.: Status and perspectives in the assessment of drug treatment in BPH. Perspectives in the Drug Treatment of BPH. VIIth International Symposium, Bovenau, Germany, October 21-23, 1994.
4. Garraway, M.: Epidemiology of, and screening for BPH. Benign Prostatic Hyperplasia: Advanced Course on Therapeutic Modalities and Decision Making. San Lorenz de El Escorial, Spain, October 7-9, 1994.
5. Glynn, R. J., Champion, E. W., Bouchard, G. R., Silbert, J. E.: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Amer. J. Epidemiol, 121, 78 (1985).
6. Goldschmidt, A.: Economic aspects in the treatment of BPH. Perspectives in the Drug Treatment of BPH. VIIth International Symposium, Bovenau, Germany, October 21-23, 1994.
7. Helpap, B., Oehler, U., Weisser, H., Bach, D., Ebeling, L.: Morphology of benign prostatic hyperplasia after treatment with Sabal extract IDS 89 or placebo. J. Urol. Pathol., 3, 175 (1995).
8. Romics, I., Schmitz, H., Frang, D.: Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int. Urol. Nephrol., 25, 565 (1993).
9. Rotkin, I. D.: Epidemiology of benign prostatic hypertrophy. Review and speculations. In: Grayhack, J. T. (ed.): Benign Prostatic Hyperplasia. DHEW Publ. US Govt. Printing Office, Washington DC 1976, pp. 105-117.
10. Szécsi, M., Tóth, I., Julesz, J., Faredin, I., Behnke, B.: Effect of Strogen forte extract on the testicular Δ-5 3β-hydroxysteroid dehydrogenase activity in vitro (Abstract). Eur. J. Endocrinol., 130 (S), 120 (1994).
11. Tóth, I., Szécsi, M., Julesz, J., Faredin, I., Behnke, B.: Effect of Strogen forte extract on the prostatic 5α-reductase activity in vitro (Abstract). Eur. J. Endocrinol., 130 (S2), 53 (1994).
12. 5-3β-hydroxysteroid dehydrogenase and prostatic 5α-reductase activities in rats and humans by Strogen forte extract. Int. Urol. Nephrol., 28, 337 (1996).
13. Watanabe, H.: Natural history of benign prostatic hypertrophy. Ultrasound Med. Biol., 12, 567 (1986).
14. Weisser, H., Tunn, S., Behnke, B., Krieg, M.: Effect of Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia. Prostate, 1995 (accepted for publishing).
15. Report of the Hungarian National Urological Institute, Debrecen, 1995 and 1996 (in Hungarian).